3 years ago

Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives

Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives
Luigi Scipione, Valentina Noemi Madia, Giovanni Pupo, Roberto Di Santo, Annarita Fiorillo, Antonella Messore, Luca Pescatori, Marina Gramiccia, Francesco Saccoliti, Roberta Costi, Trentina Di Muccio, Andrea Ilari, Gabriella Angiulli, Gianni Colotti

Abstract

The study presented here aimed at identifying a new class of compounds acting against Leishmania parasites, the causative agent of Leishmaniasis. For this purpose, the thioether derivatives of our in-house library have been evaluated in whole-cell screening assays in order to determine their in vitro activity against Leishmania protozoan. Among them, promising results have been achieved with compound RDS 777 (6-(sec-butoxy)-2-((3-chlorophenyl)thio)pyrimidin-4-amine) (IC50 =29.43 µM), which is able to impair the mechanism of the parasite defence against the reactive oxygen species by inhibiting the trypanothione reductase (TR) with high efficiency (Ki 0.25 ± 0.18 µM). The X-ray structure of L. infantum TR in complex with RDS 777 disclosed the mechanism of action of this compound that binds to the catalytic site and engages in hydrogen bonds the residues more involved in the catalysis, namely Glu466', Cys57 and Cys52, thereby inhibiting the trypanothione binding and avoiding its reduction.

Publisher URL: http://tandfonline.com/doi/full/10.1080/14756366.2016.1250755

DOI: 10.1080/14756366.2016.1250755

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.